By Vickys Kourlibini The green light for the Share Capital Increase of up to 58 million euros, with cash payment and a right of preference in favor of old shareholders, given yesterday at the extraordinary general meeting of shareholders of Lavipharm. 59.22% of the shareholders attended the meeting, in person or by proxy. The amount […]
Tag: lavipharm
‘Green light’ from Lavipharm shareholders for AMK
By Vickys Kourlibini The extraordinary general meeting of the shareholders of Lavipharm was completed at the company’s headquarters in Peania, which had as its object the increase of the company’s share capital by 58 million euros, in favor of the existing shareholders, as well as the amendment of the listed company’s articles of association. At […]
Approval of AMK by Lavipharm’s General Assembly
By Vickys Kourlibini The extraordinary general meeting of the shareholders of Lavipharm was completed at the company’s headquarters in Peania, which had as its object the increase of the company’s share capital by 58 million euros, in favor of the existing shareholders, as well as the amendment of the listed company’s articles of association. At […]
Lavipharm SA: Acquisition of transdermal pressure product rights for 34 million euros
The Board of Directors of Lavipharm SA approved by unanimous decision of the present members the granting of a license for the acquisition by the company of an intangible asset of a profitable business activity, consisting of all the exclusive rights of ownership, production, marketing and distribution throughout the world, except the .P.A., a transdermal […]
Lavipharm: EGS on 30/8 for AMC 58 million euros
An Extraordinary General Meeting of the shareholders of Lavipharm for August 30, with the purpose of increasing the company’s share capital by 58 million euros in favor of the existing shareholders, as well as to amend the articles of association, is called by the company’s board of directors. As stated in the relevant announcement: “According […]
Lavipharm: GA on 30/6 for reverse split and capital reduction for losses offset
The increase of nominal share value from € 0.10 each share to € 0.30 each share, with a simultaneous reduction of the total number of shares by merging the old ones in a ratio of three old to one new, as well as the reduction of the share capital by € 127,010 .804,00 for compensation […]
Lavipharm’s turnover in the nine months of 2021 is at 28.42 million euros
Lavipharm recorded increased sales, but also EBITDA on an annual basis in the first nine months of 2021. Consolidated Sales amounted to Euro 8.86 million in the third quarter of 2021 and Euro 28.42 million for the period 01.01.2021-30.09.2021 against Euro 9.13 million and Euro 27.39 million in corresponding periods of the fiscal year 2020, […]